Work

Excellent efficacy of trastuzumab deruxtecan in a patient with HER2-positive advanced breast cancer complicated by pulmonary lymphangitic carcinomatosis: a case report and literature review

Year: 2025

Type: article

Abstract: Trastuzumab deruxtecan (T-DXd or DS-8201), as a novel antibody-drug conjugate, has demonstrated good efficacy in HER2-positive advanced breast cancer. However, its effectiveness in treating pulmonary lymphangitic carcinomatosis (PLC) has not been previously reported. This paper presents a case of a HER2-positive advanced breast cancer patient who experienced disease progression after treatment with trastuzumab and pertuzumab. The patient developed multiple metastases along with PLC and subsequently received T-DXd treatment, achieving 14.2 months of progression-free survival (PFS). This case is the first to reveal the therapeutic potential of T-DXd in breast cancer patients with PLC.

Source: Frontiers in Pharmacology

DOI: 10.3389/fphar.2025.1574286

Authors: Simin Luo, Jie Chai, Linxiaoxiao Ding, Song Tang

Institutions: Sun Yat-sen University, Sun Yat-sen Memorial Hospital, First Affiliated Hospital of Guangdong Pharmaceutical University

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801